熱門資訊> 正文
葛兰素史克（GSK）的Jemperli在直肠癌第二阶段试验中实现目标
2026-07-14 07:16
- GSK (GSK) said that interim results from the phase 2 AZER-1 trial showed that patients with a certain type of rectal cancer given Jemperli (dostarlimab) showed a sustained complete clinical response rate at one year.
- Enrolled patients had stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer, which represents about 5%-10% of this type of cancer.
- GSK noted that if approved, Jemperli would become the first immunotherapy that could eliminate or delay the use of chemotherapy, radiation, and surgery for this group of rectal cancer patients.
More on GSK
- Is GSK Quietly Becoming An Oncology Powerhouse?
- Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors
- GSK plc (GSK) M&A Call Transcript
- U.S. advises against Congo travel after second American aid worker contracts Ebola
- GSK partner Hansoh posts late-stage trial win for lung cancer drug in China
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
